title: An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors.
abstract: This report discusses the principles of reproductive toxicity risk assessment for biopharmaceuticals blocking the PD-1/programmed cell death ligand 1 (PD-L1) pathway, which have been developed for the treatment of patients with advanced malignancies. The PD-1/PD-L1 pathway is a T-cell co-inhibitory pathway that normally maintains immune tolerance to self. Its role in pregnancy is to maintain immune tolerance to the fetal allograft. In cancer patients, this signaling pathway is hijacked by some neoplasms to avoid immune destruction. PD-1/PD-L1-blocking agents enhance functional activity of the target lymphocytes to eventually cause immune rejection of the tumor. A therapeutic blockade of PD-1/PD-L1 pathway that occurs at full target engagement provides a unique challenge to address the risk to pregnancy because disruption of the same pathway may also reduce or abrogate maternal immune tolerance to the fetal alloantigens inherited through the father. Typically, nonclinical reproductive and developmental toxicity (DART) studies in animals (rats and rabbits) with clinical drug candidates are conducted to identify potential risk in humans and to determine exposure margin for the effects on reproduction as part of the risk assessment. However, for biopharmaceuticals for which the desired mechanism of action cannot be separated from potential deleterious effects to the fetus and when the only relevant toxicology species is nonhuman primate (NHP), the risk to reproduction can be predicted by a mechanism-based assessment using data generated from murine surrogate models as supportive information without conducting DART in NHPs. Such an approach has been used in the evaluation of pregnancy risk of anti-PD-1 agent, pembrolizumab, and has been demonstrated as an important alternative to performing DART studies in NHPs.
authors.affiliation: Merck Research Laboratories, Kenilworth, New Jersey.
authors.forename: Frederique M
authors.initials: FM
authors.lastname: Poulet
authors.affiliation: Merck Research Laboratories, West Point, Pennsylvania.
authors.forename: Jayanthi J
authors.initials: JJ
authors.lastname: Wolf
authors.affiliation: Merck Research Laboratories, West Point, Pennsylvania.
authors.forename: Danuta J
authors.initials: DJ
authors.lastname: Herzyk
authors.affiliation: Merck Research Laboratories, West Point, Pennsylvania.
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: DeGeorge
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis; D005260:Female; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy; D010920:Placenta / Q000187:drug effects / Q000378:metabolism; D011247:Pregnancy; D012098:Reproduction / Q000187:drug effects*; D018570:Risk Assessment; D015398:Signal Transduction; D023041:Xenograft Model Antitumor Assays
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; C582435:pembrolizumab
keywords: PD-1/PD-L1; alternative models; biopharmaceuticals; fetus; pregnancy; reproductive toxicity; risk assessment